The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
First-line chemotherapy plus cetuximab in patients grouped according to prognostic risk factors: Analysis of the CRYSTAL and OPUS studies.
Gunnar Folprecht
Consultant or Advisory Role - Bristol-Myers Squibb; Merck KGaA; Roche
Honoraria - Merck KGaA; Novartis; Pfizer; Roche
Research Funding - Merck KGaA
Eric Van Cutsem
Consultant or Advisory Role - Merck KGaA
Research Funding - Merck KGaA
Carsten Bokemeyer
Consultant or Advisory Role - Amgen; Merck KGaA; Sanofi
Honoraria - Amgen; Merck KGaA; Sanofi
Research Funding - Merck KGaA
Michael Schlichting
Employment or Leadership Position - Merck KGaA
Steffen Heeger
Employment or Leadership Position - Merck KGaA
Claus-Henning Kohne
Honoraria - Merck KGaA; Pfizer